Member Info for marik

12 is a hard nut, I've had a chartist message me about it being hammered for a while with an indication that it will break around "1pm when the upward wedge is close to complete on the 5m chart".

Whatever that means. I am more into fundamentals.

@Skeletor, you are right. We can use ODX as an example. I just pointed this out to @CaptainSwag regarding the rumour/insider_info report from 10th/11th Jan, and here are the elephants in the room:

The first elephant is that the report not only got the day wrong, it also postulated that there was immanency in a placing at 5p. It didn't provide context of potential upside and clearly had to be an insider (considering the likelihood of NDAs).

The second elephant is that there is a real possibility that whoever leaked this information (or those associated) took advantage of those going short along with playing the market.

The third elephant, which I am surprised at is, that no one has questioned this?

The share price went down, and just imagine, everyone who spoke up would have been called a ramper.

@Okehurst1 that's 440M people jus in the EU and many more millions outside. ODX have 32M annual capacity and I think they are in a very strong place to start expanding. As big orders start flowing in...

@CaptainSwag I like the elephant analogy. It is more of a herd of elephants:

The first elephant is that the report not only got the day wrong, it also postulated that there was immanency in a placing at 5p. It didn't provide context of potential upside and clearly had to be an insider (considering the likelihood of NDAs).

The second elephant is that there is a real possibility that whoever leaked this information (or those associated) took advantage of those going short along with playing the market.

The third elephant, which I am surprised at is, that no one has questioned this?

So the rumour/insider_info report didn't give any context to the potential 440m EU self-test market? So just suggested that traders should short?

Someone else mention that this report said that a placing would happen around the 11th of Jan. Did they get their dates, price and imminent nature of the placing wrong?

Because of the lack of context, there could be investors who are short and have lost a lot of money.

" This didn’t seem to be a problem in mice, with their improved survival rates on pro-Dox, and the dose escalation suggests it is not a problem in humans."

Very good point. If we go by the pre-clinical data, the tumour would have had a dramatic concentration of doxorubicin even at 54mg/m2. This is because a large proportion of it would have cleaved at the FAP-a tumour microenvironment as opposed to off-target.

@Prime, I was told by @CaptainSwag that there was a report floating around on the 9th/11th of Jan regarding a fund raise. I was wondering if this report contained any reference to successful CE-mark for self-test use?

@Latino or @CaptainSwag, do you guys know if the rumour report article contained any mention of successful CE marking of the antigen test for self-test use?

I know many investors were taken in by the rumour report and didn't question it. Was there any mention of approval of the CE marking for self-testing?

When did this rumour report start?

"EU is a bigger market so go for it. BoJo & co are more concerned about buying party food and drinks then any UK COVID stuff anyway."

LOL, BoJo is also on the cusp of something great.

You make a very good point @Latino. The placing could well be cancelled. I wouldn't be surprised considering my previous post (below for reference).

----
I believe ODX are very undervalued and part of the reason for this is the negative sentiment around the company based on previous confusion which was fortunately clarified over the last few days. This may well have resulted in the dramatic rise in the share price over the last few days.

Firstly todays news:

- Omega announces it has successfully CE marked its VISITECT® COVID-19 antigen test for self-test use.
- £14m market cap company
- manufacturing capacity of 2.67 million/month
- now able to sell in large volumes to Europe and other countries accepting CE
- At a small £3 per test, the revenue generated will be hitting 7x the current market cap.
- revenue potential of c. £100m per annum

Clarification of previously held misconceptions:

- ODX has runway with no immediate urge to fund raise
- multiple approvals in the pipeline
- No money owed to DHSC
- FDA application has been made for professional use
- numerous other products (HIV, food intolerance and allergy)

With Covid spreading throughout the US and other parts of the world and people still dying, it is exceptionally important that testing is paramount to help reduce the burden on health cares around the world.

A very good tweet by Myles:

https://twitter.com/MylesMcNulty/status/1489164091998576642

@Bella you are welcome.

In case anyone missed the memo:

- ODX has runway with no immediate urge to fund raise

From the RNS:

"As per the announcement of 19 January, the Company has significant cash resources. Accordingly, there is no immediate need to raise additional capital..."

@donotpanic, todays price is very undervalued. Look at the price on Jan 2020 pre-covid: 15p.

Since then Collin and team ODX have expanded substantially with a personal manufacturing capacity of 2.67 million/ month. Approval for self-test throughout Europe and many other countries that accept CE marking. With that in mind the price should be multiples higher than where we are right now.

As for future target after a sales RNS, this could go back to all time highs (will have to wait and see).

GLA

@RegulatorUK yes you are spot on. It's all happening outside of the UK, with ODX able to sell in all of EU and all countries that accept the CE mark. Also don't forget if CE marking for self use has been granted, then FDA approval for professional use can't be that far behind!

I believe ODX are very undervalued and part of the reason for this is the negative sentiment around the company based on previous confusion which was fortunately clarified over the last few days. This may well have resulted in the dramatic rise in the share price over the last few days.

Firstly todays news:

- Omega announces it has successfully CE marked its VISITECT® COVID-19 antigen test for self-test use.
- £14m market cap company
- manufacturing capacity of 2.67 million/month
- now able to sell in large volumes to Europe and other countries accepting CE
- At a small £3 per test, the revenue generated will be hitting 7x the current market cap.
- revenue potential of c. £100m per annum

Clarification of previously held misconceptions:

- ODX has runway with no immediate urge to fund raise
- multiple approvals in the pipeline
- No money owed to DHSC
- FDA application has been made for professional use
- numerous other products (HIV, food intolerance and allergy)

With Covid spreading throughout the US and other parts of the world and people still dying, it is exceptionally important that testing is paramount to help reduce the burden on health cares around the world.

The Avacta RNS today was sufficient to indicate that AVA6000 is safe in humans at the dose of 80mg/m2. None of the patients would have experienced a dose-limiting toxicity (DLT). Amongst other markers, they will have tested Cmax (maximum plasma concentration) along with exposure and half-life with renal clearance. DLTs are important for the chemotherapy related cardiotoxicity for which assessments would have been made (incl. LV EF, LV Vol, Dyst F. etc.). All of which would have been well within acceptable levels. Also, for escalation to occur, all the combined data would have to be as a whole positive. Along with DLTs, the Cmax and t1/2 are key in to understanding systemic issues. This is resounding news that AVA6000 works at 80mg/m2 with NO and without doubt an MTD will be found for progressing to phase 1b. Remember that doxorubicin is well characterised in humans and the presence of pro-Dox is being escalated and as such the safety profile of the cleaved preCISION chemistry is also a resounding yes. Meaning that if dose escalation has worked for AVA6000, then the underlying mechanism will be the same for AVA3996. Once this news sinks in for Institutional Investors and large holders, the market will react accordingly. Very positive news.

GLA

@The.Manc I believe the DAM relationship will certainly be revisited with the potential to be more encompassing.